year left
short interest float
galm pharmaceut glmd clinic stage biopharmaceut compani
develop lead product candid aramchol synthet fatti acid/bil acid conjug
treatment non-alcohol steatohepat nash aramchol oper via
regul stearoyl-coa desaturas increas flux transsulf
pathway maintain redox homeostasi improv fatti acid oxid target
critic reduc fatti acid accumul hepatocyt clear exist fatti acid
deposit galm complet phase iia studi demonstr statist signific
reduct liver fat patient receiv aramchol preclin studi also
perform contribut elucid product mechan
action also demonstr improv steatosi inflamm fibrosi
compani current conduct random double-blind placebo-control phase iib
studi arrest aramchol nash also on-going investigator-initi
phase iia trial arriv aramchol patient hiv-associ lipodystrophi
point discuss
galm develop once-daili oral treatment nash catalyst
expect near-term galm lead product candid aramchol novel daili
oral avail synthet fatti acid/bil acid conjug develop non-alcohol
steatohepat nash liver diseas affect popul drug
function reduc lipid product hepatocyt via regul stearoyl-coa
desaturas increas mitochondri fatti acid b-oxid
compon nash diseas pathogenesi candid produc posit phase iia
data given mechanist rational product nash highlight upcom
potenti catalyst data arriv expect februari
believ may implic top-lin arrest result expect late
may earli june
posit phase iia clinic data support potenti success arrest studi
galm complet random double-blind placebo-control phase iia trial
evalu aramchol patient nafld nash sixti patient random
receiv aramchol placebo patient aramchol group experienc signific
februari top-line data phase ii arriv studi aramchol
patient hiv-associ lipodystrophi non-alcohol fatti liver diseas
late may earli june top-line result phase iib arrest studi
aramchol nash
pre-phas meet fda aramchol nash
initi phase iib/iii studi aramchol patient hiv-
associ lipodystrophi nash
analyst certif disclosur pleas see page
decreas liver fat compar increas patient placebo arm
primari endpoint trend toward mild weight reduct increas level serum adiponectin
subject treat high dose aramchol adiponectin improv insulin sensit act anti-oxid
anti-inflammatori anti-fibrot effect liver safeti profil favor seriou
advers event report either studi arm could becom strong differenti factor
program nash treatment space
arriv data upcom may read-through arrest studi consid arriv result
expect immin first quarter ahead arrest data late may earli june import
consider whether find arriv translat success arrest feel data liver fat
reduct arriv provid invalu insight outcom arrest particularli
primari endpoint liver fat reduct also potenti secondari endpoint fibrosi improv
given fat reduct translat fibrosi reduct time although still greatli unknown
fat lower length time need potenti posit read-through greatli base similar
treatment popul rational aramchol use popul critic aspect trial design also
note posit arriv data could translat success arrest potenti success arrest
remain irrespect outcom arriv particularli due differ treatment length
potenti direct fibrosi improv given aramchol demonstr activ preclin dig
compon analysi greater detail
pathogen similar nash hiv-associ lipodystrophi hypothes
nash pathogenesi focu lipotox driven multifactori increas free fatti acid ffa
concurr increas triglycerid tg accumul within contribut factor
increas ffa includ increas dietari intak satur fatti acid sfa de novo
dnl increas lipolysi adipos tissu via insulin resist importantli insulin resist
thought critic develop oxid stress lipotox nash view
increas dietari fat intak dnl potenti driver insulin discuss
follow paragraph process also implic patient hiv-associ lipodystrophi
nafld repres meaning pathogen overlap nash patient
hiv-associ lipodystrophi nafld greatli driven use antiretrovir therapi art
caus dyslipidemia induc fatti liver insulin resist oxid caus
increas ffa cytokin decreas adiponectin product iron liver affect
insulin resist perpetu process lead greater ffa traffic hepatocyt lead
greater oxid stress lipotox furthermor patient hiv receiv art also
experi increas de novo lipogenesi well level tg low-dens lipoprotein cholesterol
across board patient hiv-associ lipodystrophi nafld similar
pathogen featur nash patientsinclud metabol featur insulin resist
critic aspect diseas view
aramchol mechanist rational aramchol mechan action two-part compound
regul stearoyl-coa desaturas increas flux transsulf pathway
maintain redox homeostasi improv fatti acid enzym catalyz reaction
need produc monounsatur fatti acid mufa build block complex
lipid tg regul result less lipid product hepatocyt could
amelior steatosi inflamm result fibrosi second effect aramchol enhanc
transsulf pathway lead greater glutathion gsh synthesi higher gsh/oxid
gsh ratio pathway thought respons improv fatti acid b-oxid
process fatti acid molecul broken relat diseas pathogenesi aramchol
mechanist affect de novo lipogenesi via downregul well fatti acid b-
oxid repres metabol ffa thu compound target critic aspect diseas
pathogenesi hiv-associ lipodystrophi nafld well nash give galm
trial design comparison obviou consider potenti success upcom arriv
arrest studi clinic trial design provid side-by-sid comparison studi
galm prior phase iia studi figur studi show signific placebo-adjust rel
reduct liver fat mg aramchol follow week treatment box indic key
differ trial design arriv arrest rel prior studi includ higher
dosag mg versu mg highest dose longer treatment period month arrest versu
week sever patient popul patient nafld score enrol prior
studi vers na greater arrest view chang like improv
probabl success importantli primari endpoint liver fat reduct consist across studi
though arriv use mri-pdff assess trial use mr note mri-
pdff provid fat imag entir liver mr biochem measur liver fat region
interest arrest compani use multipl site repeat measur techniqu
found highli correl overal look arriv potenti de-risk
moment aramchol nash believ result valuabl assess compound potenti
arrest howev also note due longer treatment period aramchol demonstr
direct anti-fibrot effect potenti success arrest may remain irrespect outcom
iruarrizaga-lejarreta et al role aramchol steatohepat fibrosi mice hepatolog commun
nafld nash primarili
enrol nafld
nafld
obes pre- type
week
adiponectin level weight
na may less
sever diseas liver tg
least
hepatocyt steatosi
pdff week
month
resolut nash
liver fat via
na greater liver fat
via mr
gener popul make nash
fda approv treatment nash associ liver failur cardiovascular
diseas nash quickli becom lead caus liver transplant us driven larg
grow number patient lack fda approv therapi better treatment major liver
diseas hepat patient nash progress fibrosi cirrhosi mortal rate ten
despit nash affect liver nafld independ risk factor cardiovascular diseas
cvd cvd common caus morbid mortal patient popul nash patient
also twice risk cardiovascular complic compar without diseas current therapi
use off-label gear toward manag patient comorbid diabet dyslipidemia
obes strong need treatment directli impact diseas progress lead liver failur
cardiovascular complic aramchol target two critic stage nash steatosi fibrosi
preclin clinic data support potenti improv issu
signific market opportun nash market nash wide recogn untap
blockbust market due size market burden diseas lack treatment option
specif larg exist pool nash patient estim million us
eu diseas preval expect continu increas along relat metabol condit
diabet obes consid treatment option current approv nash healthcar
cost late stage nafld substanti clear opportun drug maker creat therapi
provid pharmacoeconom benefit treatment patient underserv diseas
nash attract substanti pharma interest still rel earli day nash
space pipelin clinical-stag product robust seem grow everi day pharma compani
valid space interest demonstr partnership agreement
early-stag blockbust acquisit premium exampl allergan nyse agn
acquir tobira therapeut billion follow phase iib data indic fibrosi improv nash
patient gilead acquir nimbu therapeut nash program focus inhibitor
total consider billion prior phase data also takeda over-the-counter tkpyy rna-focus
nash program arcturu arct recent ink million drug discoveri
agreement hemoshear privat
third quarter financi novemb galm report financi result third quarter
research develop expens million compar million period
gener administr expens million third quarter compar million
third quarter compani report net loss million per share third
quarter compar net loss million per share period
decemb compani cash cash equival market secur total million
compar million decemb
tabl content
aramchol once-daili oral therapi nash
mechan action
caus pathogenesi
symptom diagnosi
phase iia trial aramchol patient nafld nash
on-going phase iib arrest trial aramchol nash
arriv phase iia trial aramchol hiv-associ lipodystrophi nafld
drug develop
risk invest
galm clinical-stag biotechnolog compani develop aramchol treatment non-alcohol
steatohepat nash nash second stage non-alcohol fatti liver diseas nafld begin
hepat fat accumul lead inflammatori state nash sometim follow fibrosi cirrhosi
eventu hepatocellular carcinoma and/or hepat failur aramchol oper via regul
stearoyl-coa desaturas increas flux transsulf pathway maintain redox
homeostasi improv fatti acid oxid target critic reduc fatti acid accumul
hepatocyt clear exist fatti acid deposit galm complet phase iia studi demonstr
signific reduct liver fat patient receiv aramchol preclin studi also perform
contribut elucid product mechan action also demonstr improv
steatosi inflamm fibrosi compani current conduct random double-blind placebo-
control phase iib studi aramchol nash top-lin result expect second quarter
aramchol once-daili oral therapi nash
aramchol arachidyl amido cholano acid potenti first-in-class oral once-daili synthet fatti acid-bil acid
conjug fabac develop treatment nonalcohol steatohepat nash chemic
structur aramchol display figur aramchol contain cholic acid conjug satur
fatti acid via amid bond conjug exist natur bodi must synthes aramchol
initi intend solubil cholesterol bile prevent treatment gallston format
anim studi howev demonstr compound abil reduc fat content liver anim
fed high-fat diet subsequ preclin studi variou anim model reveal similar result suggest
compound offer multipl advantag includ decreas steatosi inflamm fibrosi
safadi et al phase-ii random doubl blind placebo-control trial aramchol treatment non
alcohol fatti liver diseas nafld nash european associ studi liver meet
figur structur aramchol
galm conduct phase iia random double-blind placebo-control trial aramchol patient
biopsy-confirm nafld nash result show three month daili aramchol administr
safe significantli reduc liver fat content dose-depend manner compani current conduct
random placebo-control phase iib arrest aramchol nash last patient
treatment phase late februari three month follow top-lin result releas like
late may earli june also on-going investigator-initi phase iia arriv
aramchol patient hiv-associ lipodystrophi nafld top-lin result studi expect
first quarter result could implic outcom galm nash trial
mechan action
aramchol mechan action two-part compound regul stearoyl-coa desaturas
increas flux transsulf pathway maintain redox homeostasi improv fatti acid
enzym catalyz reaction need produc monounsatur fatti acid mufa
build block complex lipid regul result less lipid product
hepatocyt could amelior steatosi inflamm result fibrosi second effect aramchol
enhanc transsulf pathway lead greater glutathion gsh synthesi higher
gsh/oxid gsh ratio pathway thought respons improv fatti acid b-oxid
process fatti acid molecul broken summari effect aramchol associ
less lipid product hepatocyt via regul increas mitochondri fatti acid b-
oxid conclus support recent preclin studi conduct iruarrizaga-
lejarreta et al publish
inhibit impact liver steatosi enzym locat endoplasm reticulum
respons desatur satur fatti acid monounsatur fatti acid mufa two
main sourc fatti acid fa synthesi fat diet smaller build block bodi adipos
iruarrizaga-lejarreta et al role aramchol steatohepat fibrosi mice hepatolog commun
tissu respons transform fa mufa constitut build block
complex lipid phosphoplid triglycerid cholesteryl ester vitro vivo studi rodent
shown over-express lead metabol syndrom indic signific role enzym
pathogenesi dyslipidemia atherosclerosi obes diabet nash
sever studi last two decad shown rate-limit enzym synthesi
mufa creat bottle-neck product vldl particl potenti good point
inhibit process upregul present liver brown adipos muscl tissu thu
contribut accumul mufa caus increas fatti acid storag liver decreas energi
expenditur increas insulin resist result hepat steatosi fatti liver metabol syndrom
condit seen patient diabet obes fatti liver diseas nonalcohol fatti liver diseas
nafld nash
aramchol regul function decreas mufa synthesi also increas fatti acid b-
oxid fat metabol lead modul steatosi earli studi aramchol demonstr
compound regul express liver microsom mice still avoid atherogen side
effect aramchol also enhanc cholesterol efflux macrophag two-fold increas fecal sterol
output significantli decreas plasma cholesterol recent studi publish
hepatolog commun confirm mechan action aramchol show improv
steatosi inflamm fibrosi also specif measur oxid
investig preclin rodent model show although inhibit protect diet-induc
obes hepat steatosi insulin resist accumul start materi use may also
promot inflamm skin barrier alter atherosclerosi steatohepat pancreat beta cell dysfunct
fact may crucial factor suppress inflammatori diseas transport pro-inflammatori
satur fatti acid less biolog activ monounsatur fatti acid-enrich neutral lipid therefor
complet inhibit may lead undesir effect particularli perpetu cardiovascular diseas
fatti acid build-up skin pancreat dysfunct
effect aramchol cholesterol liver fat infiltr valid numer vitro vivo
studi earli anim studi reveal aramchol abil prevent cholesterol crystal dissolv pre-
form crystal rodent fed high fat diet hfd work gallston suscept mice
demonstr aramchol could prevent gallston format dissolv pre-exist gallston interestingli
fabac found wide-rang metabol effect includ abil decreas serum cholesterol
concentr importantli aramchol treatment reduc liver fat content rodent model
environment predispos develop fatti liver term safeti aramchol treatment increas
atherosclerosi standard laboratori mice mice bred mutat increas risk
absenc atherogen properti import safeti paramet aramchol recent studi
leikin-frenkel et al fatti acid bile acid conjug inhibit hepat stearoyl coenzym desaturas non-
atherogen archiv medic research
leikin-frenkel et al fatti acid bile acid conjug inhibit hepat stearoyl coenzym desaturas non-
atherogen archiv medic research
iruarrizaga-lejarreta et al publish conduct character mechan action
aramchol achiev evid concurr reduct steatosi inflamm fibrosi
studi perform model elucid mechan action aramchol result show
improv steatosi inflamm fibrosi investig conduct preclin studi
aramchol mice treat methionine- choline-defici diet common diseas model use
studi anim receiv diet contain cholin methionin week
led develop steatohepat fibrosi control anim receiv typic diet contain
mg/kg cholin methionin two week receiv either diet mice treat either
mg/kg/day aramchol vehicl vehicl alon variou biochem histolog assess perform
serum liver sampl includ assess steatosi inflamm fibrosi steatosi
analyz via sudan stain fat-solubl dye identifi lipid triglycerid lipoprotein
inflamm assess via stain identifi hepat monocyt macrophag
kupffer cell data present figur result indic qualit histolog improv
concurr signific decreas steatosi anim receiv aramchol rel placebo
inflamm also reduc aramchol treat anim demonstr signific decreas
posit cell compar placebo signific decreas posit cell
figur assess steatosi sudan inflamm
iruarrizaga-lejarreta et al role aramchol steatohepat fibrosi mice hepatolog commun
investig also assess liver fibrosi variou histolog marker collagen siriu red
data present figur result indic reduct siriu red stain protein
signific anim receiv aramchol rel placebo respect
figur assess fibrosi via collagen siriu red
import compon studi light aramchol mechan measur glutathion
gsh oxid glutathion gssg ratio fatti acid data present figur data
anim receiv aramchol present teal vehicle-tr mice present grey result
indic vehicle-tr anim reduct gsh/gssg indic oxid stress increas
hepat fatti acid fa contribut steatosi anim receiv aramchol improv
gsh/gssg ratio note along decreas hepat fa indic avers oxid stress hepat
fa accumul find particularli import context aramchol mechan action
though occur part increas flux transsulf pathway maintain redox homeostasi
preclin result serv evid support hypothesi given increas gsh/gssg decreas
figur chang gsh/gssg fa aramchol teal vehicl grey
investig also conduct experi assess impact aramchol collagen product
human hepat stellat cell result indic regul messeng ribonucl acid mrna
data present figur import consid main
produc collagen liver contribut fibrosi note collagen accumul
gener signific aspect fibrosi data show direct effect aramchol
highlight potenti anti-fibrot effect compound overal find posit relat
potenti product treat nash warrant addit investig clinic studi
figur human product mrna
taa model indic improv liver fibrosi investig assess aramchol preclin
studi use taa model util rodent studi fibrosi model anim inject
thioacetamid taa induc liver fibrosi process occur independ steatosi inflamm
mean may speak direct effect fibrosi anim receiv mg taa per bodi weight twice
weekli week aramchol concurr administ mg/kg/day rat receiv control
fibrosi stage use ludwig batt stain system follow paramet
stage portal fibrosi mild fibrou expans portal tract
stage periport fibrosi fine strand connect tissu zone rare portal-port septa
stage cirrhosi bridg nodular regress
result present figur indic lower fibrosi score taa anim receiv mg/kg/day
aramchol compar untreat
figur fibrosi score taa model aramchol treatment
aramchol reduc liver fat content rodent model receiv high cholesterol diet one studi
examin impact aramchol diet-induc fatti liver rat hamster rodent fed hfd
also given aramchol show remark improv variou hepat metabol paramet
twenty-four old mice fourteen old hamster divid treatment control group
anim fed lithogen diet follow composit
aramchol-tr hamster regular rodent show contain cholesterol palmit acid
aramchol-tr mice regular rodent show contain butter cholesterol cholic acid
aramchol mg/kg/d given oral gavag salin suspens control anim receiv
volum salin treatment time vari three ten week fatti liver score use assess fat
liver content rate fat content scale use light microscopi score assess follow
visibl fat
liver surfac infiltr fat
figur show fatti liver score anim treatment aramchol led signific reduct fatti
liver score speci compar treatment mean score control hamster versu
aramchol-f hamster mice score respect hepat lipid/protein
gilat et al prevent diet-induc fatti liver experiment anim oral administr fatti acid bile
ratio also improv across group liver fat concentr measur milligram per lipid per gram liver
tissu decreas aramchol feed aramchol shown decreas liver fat content avoid
figur fatti liver score control aramchol-f anim
effect aramchol fat liver content nafld-induc rodent one studi mice fed high fat
diet induc nafld anim treat aramchol assess drug abil reduc liver fat
aramchol significantli decreas total liver lipid approxim week
signific decreas level diglycerid triglycerid anim continu fed
high-fat diet treatment aramchol also result decreas plasma fatti acid ratio suggest scd
activ inhibit preliminari dose concentr studi well effect hepat fat reduct
primarili seen dose mg/kg/day
aramchol may lower cholesterol level suggest earli anim studi effect aramchol
limit decreas hepat fat content preliminari work rodent suggest aramchol may also lower
cholesterol level consist origin intent molecul prevent gallston format
studi gallston suscept mice fed hfd treat mg/kg/day aramchol
week experienc averag reduct plasma cholesterol compar receiv
hfd alon figur show amount serum cholesterol found control mice gray bar
aramchol-tr anim black bar cholesterol level significantli reduc aramchol-tr mice
week treatment
leikin-frenkel et al treatment preestablish diet-induc fatti liver oral fatti acid-bil acid conjug
rodent european journal gastroenteroli hepatolog
leikin-frenkel et al hypocholesterolem effect fatti acid bile acid conjug fabac mice archiv
biochemistri biophys
figur cholesterol reduct aramchol-tr mice
studi also explor mechanist underpin reduct cholesterol level find aramchol
treatment led reduc hepat cholesterol synthesi increas express gene respons convers
cholesterol bile acid increas fecal sterol output three pathway contribut lower
total cholesterol level bodi like slow progress nafld
galm conduct two chronic toxicolog studi month rat month dog
consist fda preclin toxicolog requir contract research organ cro
conduct studi report treatment-rel mortal effect bodi weight dose
mg/kg per day rat mg/kg per day dog howev dog studi decreas level
cholesterol slight increas adren gland size adren effect potenti respons
cholesterol decreas cro believ effect pharmacodynam natur instead toxic
cholesterol decreas consist drug mechan action
clinic studi drug-rel advers event patient receiv aramchol
patient treat data galm phase ii trial support continu addit
clinic studi treatment relat seriou advers event report patient receiv aramchol note
import safeti treat nash patient given need chronic administr aramchol may
accept drug diseas consid safeti profil date
non-alcohol fatti liver diseas nafld broad-spectrum condit contain sever diseas state
begin accumul fat liver ultim progress far cirrhosi diseas
hepat fat accumul steatosi due alcohol use rather caus sedentari lifestyl western
diet genet predisposit condit also associ varieti metabol effect
approxim nafld patient one compon metabol syndrom
defin sever follow condit occur simultan insulin resist obes dyslipidemia
hypertens cardiovascular clinic progress nafld depict figur begin
steatosi lead inflamm fibrosi scar cirrhosi eventu hepatocellular carcinoma
and/or hepat failur advanc stage non-alcohol steatohepat nash second stage
nafld character inflamm result oxid stress lipoapoptosi cytokin
despit high preval us treatment nash limit lifestyl modif weight loss
exercis though demand pharmacolog treatment option appar
figur diseas spectrum nafld approxim risk progress
lifesci capit shuppan et al
stage nafld nafld consid spectrum disord begin fat accumul liver
diseas progress inflamm fibrosi scar irrevers impair liver function eventu
necessit liver transplant four main stage overal continuum nafld present
stage fatti liver non-alcohol fatti liver nafl hepat fat infiltr earli stage
typic asymptomat elev liver enzym routin blood work may indic excess
liver fat content risk patient progress cirrhosi upon emerg nafl small
stage nash nash involv steatosi inflamm cellular balloon without
presenc fibrosi patient nash may still asymptomat although dull ach right upper
quadrant pain may present occas
stage fibrosi stage character persist hepat inflamm result fibrou scar
tissu hepatocyt surround vasculatur liver tissu may still remain allow hepat
function proceed normal
veld et al metabol syndrom non-alcohol fatti liver diseas annal hepatolog
shuppan et al non-alcohol steatohepat pathogenesi novel therapeut approach journal
gastroenterolog hepatolog
chalasani et al diagnosi manag non-alcohol fatti liver diseas practic guidelin
american associ studi liver diseas american colleg gastroenterolog american
stage cirrhosi advanc stage nafld tend occur sever year hepat
inflamm fibrosi patient diagnos cirrhosi typic greater year age
though earlier present report patient becom cirrhot diseas irrevers
cure liver transplant
variou stage nafld nash particular interest turn point diseas
may progress fibrosi advanc irrevers state cirrhosi exampl
patient earli stage nash one-third progress fibrosi cirrhosi within
patient becom cirrhot risk complic lead death portal hypertens liver
failur nash also associ overal mortal year follow
diagnosi nash extrem preval deadli diseas greatli unfulfil treatment option
galm develop aramchol target key aspect diseas via reduct steatosi inflamm
caus pathogenesi
though mani aspect nash well understood primarili thought manifest result sedentari
lifestyl western diet genet predisposit diseas frequent diagnos middle-ag patient
obes overweight appear tightli link metabol syndrom exampl
approxim patient one compon metabol syndrom defin
sever follow condit occur simultan insulin resist diabet obes dyslipidemia
hypertens cardiovascular lead increas risk heart diseas stroke diabet
coexist mani metabol abnorm place patient high risk
atherosclerosi subsequ cardiovascular morbid mortal
lipotox may major pathogen mechan behind hepatocyt dysfunct lead diseas
progress nash model pre-exist insulin resist combin high saturated-fat diet
increas concentr traffick free fatti acid ffa within ffa becom toxic
cell via oxid stress increas oxid ffa result product lipotox metabolit
reactiv oxygen speci result inflamm injuri hepatocyt time result fibrosi
cirrhosi oxid stress attribut ffa contribut inflammatori diseas state nash
fibrosi primarili driven hepat stellat cell activ hsc key fibrogenesi
cell produc collagen deposit extracellular matrix protein drive diseas process forward
caldwel et al natur histori non-alcohol fatti liver diseas digest diseas
mcpherson et al evid nafld progress steatosi fibrosing-steatohepat use pair biopsi
implic prognosi clinic manag journal hepatolog
veld et al metabol syndrom non-alcohol fatti liver diseas annal hepatolog
bugianesi et al expand natur histori nonalcohol steatohepat cryptogen cirrhosi
tilg et al evolut inflamm nonalcohol fatti liver diseas multipl parallel hit hypothesi
heaney et al hepatocyt senesc activ hepat stellat cell drive liver fibrosi journal hepatolog
symptom diagnosi
nash typic asymptomat character high level liver enzym thu make proper
diagnosi physician must consid associ diseas sever metabol condit includ
obes diabet dyslipidemia hypertens sedentari lifestyl metabol presenc
condit may trigger care provid test liver enzym level case prolong abnorm
physician must evalu patient nafld nash via biopsi accord american associ
studi liver diseas aasld practic guidelin nafld diagnos two criteria
presenc hepat steatosi suggest imag biopsi
possibl caus steatosi elimin includ excess alcohol consumpt g/day
medic may lead fat infiltr hepat inflamm hereditari
hepat steatosi identifi use non-invasive imag techniqu mri although liver biopsi remain
gold standard test steatosi confirm figur show exampl cell obtain liver
top panel repres slide normal liver cell tightli pack low level
collagen indic lack blue stain collagen major protein compon fibrot tissu
visual blue histolog prepar masson trichrom stain protocol middl panel
repres sampl steatosi infiltr inflammatori cell hepatocyt balloon bottom panel
show liver sampl high level fibrosi locat center imag indic strong collagen
labrecqu et al world gastroenterolog organis global guidelin nonalcohol fatti liver diseas
nonalcohol steatohepat journal clinic gastroenterolog
chalasani et al diagnosi manag non-alcohol fatti liver diseas practic guidelin
american associ studi liver diseas american colleg gastroenterolog american
angulo nonalcohol fatti liver diseas new england journal medicin
hidaka et al live donor liver transplant donor previous treat interferon hepat
viru case report journal medic case report
determin presenc degre nash pathologist use biopsi sampl determin nash activ
score na repres sum score measur three liver biopsi featur steatosi lobular
inflamm maximum score figur show three biopsi featur
one score steatosi identifi lipid retent cell cell visual count easili via
microscopi lobular inflamm assess identifi inflammatori foci site immun cell
infiltr hepatocyt balloon type cell degener produc balloon effect
determin presenc degre nash pathologist use biopsi sampl determin nash activ
score na repres sum score measur three liver biopsi featur steatosi lobular
inflamm maximum score figur show three biopsi featur
one score steatosi identifi lipid retent cell cell visual count easili via
microscopi lobular inflamm assess identifi inflammatori foci site immun cell
infiltr hepatocyt balloon type cell degener produc balloon effect
kleiner et al design valid histolog score system nonalcohol fatti liver diseas hepatolog
kleiner et al design valid histolog score system nonalcohol fatti liver diseas
indic nash prompt biopsi includ unexplain sign portal hypertens unexplain
elev liver enzym level persist month patient diabet obes
dyslipidemia studi use liver biopsi sampl found variabl predict sever injuri
initi diagnost biopsi variabl includ older age higher presenc type diabet elev
liver enzym recent studi corrobor previou theori progress advanc fibrosi posit
correl age time diagnosi degre inflamm initi biopsi
diagnosi excess alcohol intak must rule caus infect hepat also
elimin etiolog factor via neg hepat surfac antigen hepat viru antibodi
respect medic caus elev liver enzym terbinafin must consid possibl
caus hepat inflamm
sinc earli stage nash often asymptomat sinc elev liver enzym routin blood exam
incident find consensu recommend earli stage screen lack specif
sensit biomark nash also barrier earli diagnost assess patient confirm late
stage nash character cirrhosi aasld guidelin nash recommend patient
screen gastroesophag varic current evid support howev repeat liver
biopsi patient biopsy-proven nash
fda approv treatment nash given nash usual found patient type
diabet dyslipidemia obes therapeut intervent off-label focu manag
metabol comorbid current aasld guidelin recommend treat patient diseas progress
steatosi nash sinc nafld patient without steatohepat better liver
chalasani et al diagnosi manag non-alcohol fatti liver diseas practic guidelin
lifestyl modif patient present nash lifestyl modif cornerston therapi
studi shown adjust lifestyl may reduc liver enzym level may improv hepat steatosi
assess ultrasound mri one random control trial investig effect lifestyl intervent
use combin diet exercis behavior primari endpoint chang
nash histolog na week treatment trial thirty-on overweight obes individu
biopsy-proven nash random either intens lifestyl intervent ls structur
educ control week subject assign ls lost averag weight versu
control group addit subject ls group demonstr decreas na
least point post-treat na less versu control group
therapeut intervent nash patient improv lifestyl intervent often
prescrib therapi off-label approv weight reduct manag diabet manag lipid
level treatment shown figur evid efficaci nash vari among therapi
case random control studi demonstr patient benefit
figur off-label therapi use nash patient
orlistat orlistat enter lipas inhibitor weight loss use hope reduct total bodi
weight may lead steatosi improv one random control trial show improv alt
steatosi assess unfortun liver histolog conduct due loss follow
mani subject anoth random control trial show posit effect weight liver
henc evid use orlistat nash patient lack
american associ studi liver diseas american colleg gastroenterolog american
promrat et random control trial test effect weight loss nonalcohol steatohepat
zelber-sagi et al double-blind random placebo-control trial orlistat treatment nonalcohol
fatti liver diseas clinic gastroenterolog hepatolog
harrison sa et al orlistat overweight subject nonalcohol steatohepat nash random
anti-diabet drug metformin commonli prescrib off-label medic nash
sever studi investig effect metformin liver enzym liver histolog nash
unfavor result earli pilot studi show reduct insulin resist aminotransferas without
signific improv liver histolog meta-analysi found month metformin plu lifestyl
intervent led improv liver enzym liver histolog versu lifestyl intervent current
aasld guidelin state metformin signific effect liver histolog therefor
recommend specif treatment liver diseas adult
evid suggest pioglitazon anti-diabet drug thiazolidinedion famili use
treat steatohepat patient biopsy-proven nash howev long-term safeti efficaci
pioglitazon patient nash establish caution advis medic shown
lead congest heart failur bladder cancer fractur weight gain
vitamin vitamin alpha-tocopherol anti-oxid compound routin use off-label
nash given oxid stress occur within hepatocyt follow anti-oxid would
benefici effect progress nash unfortun trial vitamin nash patient
overwhelmingli heterogen differ studi use variou formul dose inclusion/exclus criteria
concomit use anti-oxid limit histolog data assess outcom still nash studi
vitamin histolog analysi employ favor improv liver enzym
steatosi inflamm balloon resolut steatohepat current recommend suggest
iu/day vitamin may improv liver histolog non-diabet adult biopsy-proven nash
consid first-lin treatment vitamin current recommend howev patient diabet
nash nafld without liver biopsi nash cirrhosi cryptogen cirrhosi
off-label treatment addit off-label intervent manag nash includ statin
ursodeoxychol acid udca fatti acid bariatr surgeri statin mainstay treat
dyslipidemia evid statin may actual improv liver enzym histolog patient
current guidelin recommend statin may safe use manag dyslipidemia patient
nafld nash howev use use specif nash recommend also allow
use fatti acid first-lin agent treat hypertriglyceridemia patient nafld current
evid advis use udca
bariatr surgeri mean treat nash via weight control remain controversi evid lack establish
treatment modal option obes nash patient long-term efficaci safeti outcom
bariatr surgeri obes patient nash cirrhosi remain unknown cost associ bariatr surgeri
would also preclud first-lin treatment million patient nash cost-effect
method treatment necessari
vernon et al systemat review epidemiolog natur histori non-alcohol fatti liver diseas non-
alcohol steatohepat adult alimentari pharmacolog
chalasani et al diagnosi manag non-alcohol fatti liver diseas practic guidelin
american associ studi liver diseas american colleg gastroenterolog american
lewi et al efficaci safeti high-dos pravastatin hypercholesterolem patient well-compens
chronic liver diseas result prospect random double-blind placebo-control multicent trial hepatolog
epidemiolog nafld nash close link metabol condit studi estim
nafld occur obes patient diabet peopl nash
may develop fibrosi progress irrevers stage cirrhosi eventu liver failur
increas risk mortal result signific cost healthcar system studi demonstr
liver-rel mortal nash patient ten time greater gener nash also third
lead indic liver transplant us behind hepat alcohol liver result
nash well project surpass hepat lead caus unit recent
studi estim million us patient nafld direct medic cost billion year
million patient eu respons approxim billion much cost
like driven nash liver-rel mortal nash patient six time greater nafld patient
preval nafld approxim us preval nash studi
util clinic laboratori ultrasound data diagnos nafld nash defin presenc
nafld elev aminotransferas concurr diabet mellitu insulin resist investig note
studi conserv inclus criteria includ patient moder sever nafld
defin hepat steatosi preval nafld eu report
us eu preval rate nafld fit broader observ rang preval western countri
preval nash estim preval rate translat total
million individu affect nash us eu per analysi figur
figur peopl affect nash us eu
individu nash
bellentani et al epidemiolog non-alcohol fatti liver diseas digest diseas
bhala et al epidemiolog natur histori patient nafld current pharmaceut design
charlton mr et al frequenc outcom liver transplant nonalcohol steatohepat unit
loomba et al global nafld epidem natur review gastroenterolog hepatolog
younossi et al econom clinic burden nonalcohol fatti liver diseas unit state
sayin et al epidemiolog nonalcohol fatti liver diseas unit state rest world clinic
market size market nash wide recogn untap blockbust market due size
market burden diseas lack treatment option specif larg exist pool
nash patient estim million us eu per analysi diseas
preval expect continu increas along relat metabol condit diabet
annual patient burden diseas stage broken figur consid
treatment option current approv nash healthcar cost late stage nafld substanti
clear opportun drug maker creat therapi provid pharmacoeconom benefit
treatment patient underserv diseas
figur variou stage nafld associ annual patient burden us
nash fibrosi
nash compens cirrhosi
nash decompens cirrhosi
demonstr size nash market us perform scenario analysi figur
analysi demonstr drug achiev penetr potenti achiev billion annual sale
analysi incorpor follow assumpt
nash patient popul assum approxim million nash patient
us eu respect may rel conserv estim
rate diagnosi assum patient nash properli diagnos current
potenti hurdl futur therapi indic nash diseas typic asymptomat
gold standard diagnosi current liver biopsi
price conservatibv assum potenti price nash therapi rang annual
sturm et al morbid obes rate continu rise rapidli unit state intern journal obes
cdc increas preval diagnos diabet unit state puerto rico morbid mortal weekli report
figur scenario analysi nash market us
galm complet multipl clinic trial aramchol demonstr favor safeti profil evid
molecul reduc liver fat patient phase trial establish pharmacokinet aramchol
data support daili oral dose result phase iia studi patient non-alcohol fatti
liver diseas nafld nash publish support use aramchol nash stage
inflamm fat accumul primari diseas driver trial found aramchol significantli
reduc liver fat content dose depend manner favor safeti profil galm current
conduct larger phase iib trial larger dose aramchol nash patient later stage diseas last
patient treatment phase late februari three month follow top-lin result
releas like late may earli june
phase iia trial aramchol patient nafld nash galm conduct phase iia
random double-blind placebo-control trial evalu aramchol patient nafld
total patient enrol liver biopsi sampl analyz assess patient nafld activ
score na patient total score consid nafld total
score consid nash
patient random receiv daili oral aramchol mg placebo treatment durat
week patient follow everi week first month monthli last month primari
endpoint differ liver fat content baselin end treatment liver fat content
measur magnet reson spectroscopi mr secondari endpoint includ serum alt level endotheli
function insulin resist adiponectin level hemoglobin level weight metabol paramet
major patient studi nafld nash fraction patient either diagnosi
display figur overal subject diagnos nafld nash fibrosi level
gener low patient fibrosi score correspond detect fibrosi
factor prior alcohol consumpt baselin biopsi find similar three studi
safadi et al fatti acid-bil conjug aramchol reduc liver fat content patient non-alcohol fatti liver
diseas clinic gastroenterolog hepatolog epub ahead print
figur fraction patient nafld nash
efficaci trial met primari endpoint liver fat reduct patient treat aramchol versu patient
placebo arm figur show rel chang mean liver fat baselin end treatment
three studi arm patient high dose aramchol group experienc signific mean liver fat decreas
compar increas patient placebo arm mean liver fat also decreas
baselin end treatment low dose aramchol group compar placebo although decreas
signific howev signific dose-depend relationship liver fat chang group
adjust age gender
figur mean chang liver fat aramchol placebo
none secondari endpoint reach statist signific although trend favor
aramchol certain measur mild weight reduct increas level serum adiponectin
associ high dose aramchol treatment respect reduct weight
metabol factor insulin resist way aramchol posit impact metabol syndrom
contribut nash marker continu monitor futur trial figur show
chang adiponectin level baselin end treatment studi arm adiponectin improv
insulin sensit act anti-oxid anti-inflammatori anti-fibrot effect liver
revers decreas adiponectin level commonli observ nafld nash patient may help facilit
benefit aramchol patient liver
figur chang adiponectin level baselin end treatment
data trial establish proof-of-concept daili oral administr aramchol posit impact
liver fat patient nafld earli stage nash data support launch larger phase iib studi
higher dose potenti enhanc efficaci maintain posit safeti profil
safeti safeti profil aramchol favor sever advers event report studi
arm occur two patient group list figur frequenc
similar across studi arm none consid treatment relat overal ae profil aramchol
similar placebo
term cardiovascular measur chang total cholesterol level treatment
impact aramchol lipid level especi import light concern regard lipid elev
intercept ocaliva nash patient alreadi elev risk cardiovascular diseas maintain
reduc cholesterol level import minim cardiovascular co-morbid aramchol also expect
administ chronic make posit overal safeti profil critic
on-going phase iib arrest trial aramchol nash multi-cent random double-blind
placebo-control phase iib studi assess aramchol patient biopsy-diagnos nash obes
pre-diabet type ii inclus obes insulin resist patient consist
potenti aramchol impact featur metabol syndrom part mechan treat nash
patient random receiv mg aramchol mg aramchol placebo daili
month follow month follow primari endpoint reduct liver fat content assess
magnet reson spectroscopi mr secondari endpoint focu histolog includ improv
fibrosi two-point improv nafld activ score na resolut nash top-lin data
expect late may earli june
particip requir biopsy-diagnos nash na greater baselin addit patient
must liver fat content least measur mr galm previous report baselin
demograph enrol patient popul includ fibrosi individu stage
stage compani note popul high risk diseas progress
repres favor nash popul clinic studi diseas like progress may
therefor easier detect improv associ treatment
arriv phase iia trial aramchol hiv-associ lipodystrophi nafld
investigator-initi random double-blind placebo control phase iia trial aramchol patient
hiv-associ lipodystrophi studi conduct univers california san
diego collabor dr rohit loomba particip enrol receiv either mg
aramchol placebo week primari endpoint reduct liver fat content assess magnet
metabol profil marker liver biochemistri enrol criteria includ lipodystrophi via clinic
radiolog assess liver fat content via mri-pdff variou risk factor sever liver
diseas top-lin result studi expect first quarter
drug develop
substanti amount drug develop interest gener nash space due larg
untap market opportun recent merger acquisit activ exampl allergan nyse agn
acquir tobira therapeut nearli premium deal worth approxim billion primarili
nash asset cenicriviroc cvc importantli asset fail achiev efficaci primari endpoint
focus reduct nafld activ score na show signific anti-fibrot effect key
secondari endpoint anoth recent buyer gilead acquir nimbu therapeut nash program
focus inhibitor total consider billion prior phase data notabl late stage
asset includ inventiva epa iva pa lanifibranor gilead selonsertib madrig
figur contain nash asset phase ii phase develop
figur phase ii compound develop nash
chemokin receptor
inhibitor
phosphodiesteras
mitochondri target
galm composit matter patent aramchol set expir march world-wide outsid israel
april israel thu compani greatli reli aramchol new chemic entiti nce
us would yield five year market exclus galm first receiv approv
compound territori compani also hold patent us sever foreign countri cover use
aramchol treatment fatti liver diseas reduct serum cholesterol treatment
hyperglycemia diabet aramchol protect use patent jurisdict except israel
compani patent aramchol use treatment fatti liver diseas expir novemb
without account potenti extens hatch-waxman amend patent applic
file second-gener fabac compound includ variou aramchol salt form give
galm potenti opportun use aramchol salt phase trial extend aramchol patent protect
beyond galm may conduct bioequival studi aramchol salt use futur
manag note patent applic file use aramchol treatment fibrosi
could provid greater patent protect compani also proprietari manufactur expertis regard
aramchol may provid addit layer protect
presid chief execut offic
mr baharaff co-found ltd serv ceo sinc presid
hold bachelor scienc degre univers london lse llb degre
cambridg univers mr baharaff held number directorship includ svp posit isramex
project ltd trusteeship manag also serv director tel-aviv museum art
execut director rubin museum
dr hayardeni join galm septemb bring year experi drug develop
part teva pharmaceut global divis prior join galm dr hayardeni serv teva
senior director head research scientif affair capac dr hayardeni establish scientif
posit teva innov compound addit dr hayardeni respons compani
relationship institut higher educ manag teva global research collabor public
dr hayardeni hold ph sackler school medicin recanati busi school tel
dr gorfin join galm may prior join galm serv senior clinic program leader
teva capac led product strategi clinic develop field multipl sclerosi
respons larg phase ii studi dr gorfin hold md phd field mri
tel-aviv univers
mr stenzler join galm june serv compani chief offic sinc februari
mr stenzler bring galm six year financi manag experi account real estat
depart ernst young llp involv financ tax audit advis account
public privat compani domest intern mr stenzler certifi hold mba
financ recanati busi school tel aviv univers ba econom account ben-
gurion univers negev
mr nehemya join galm octob compani director oper serv
compani vice presid oper sinc march mr nehemya key member manag
compani initi public offer execut thereof mr nehemya hold mba arison school
busi idc herzliya colleg manag mr nehemya member
vice presid legal affair strategi
ms holland join galm juli serv compani vice presid legal affair strategi
sinc march extens experi commerci lawyer gross kleinhendl hodak halevi
greenberg co law offic involv publicly-trad privat compani
connect corpor financ public offer merger acquisit commerci transact corpor
govern secur relat legal busi issu
ms holland hold financ recanati busi school tel aviv univers
ba econom hebrew univers jerusalem ms holland member isra bar
risk invest
consid invest galm high-risk invest galm develop stage compani
current fda approv drug portfolio sever compani attempt develop
treatment non-alcohol steatohepat galm lead program yet enter phase trial
limit data date furthermor earli indic efficaci necessarili translat posit late-stag
result phase clinic trial result signific addit expens compani may requir
addit round dilut financ compani galm may unabl obtain suffici capit
fund plan develop program regulatori risk associ develop drug
galm may receiv fda approv candid despit signific time financi invest
regulatori approv market sell drug guarante drug penetr market sale
may meet expect
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
